Yale Alumni Push Back Against Asbestos Tycoon Stephan Schmidheiny

Yale University alumni are pushing again to revoke the honorary degree given to Swiss billionaire Stephan Ernst Schmidheiny, whose asbestos-filled factories in Italy were responsible for the deaths of more than 2,000 people. Schmidheiny, 70, was sentenced to 16 years in prison and fined $15 billion in 2012 by an Italian court that found him negligent in protecting employees and nearby residents from deadly asbestos-related diseases such as mesothelioma. Schmidheiny received his honorary degree from Yale in 1996. In 2014, the university dismissed efforts by the Italy-based Asbestos Victims and Relatives Association and several Yale alumni to revoke the degree. Schmidheiny is the former chief executive officer of Eternit, a corporation specializing in fibre cement products that operated factories in four different Italian towns. The New Haven Register reported a group of 30 Yale alumni sent a letter earlier this month to university President Peter Salovey, asking him to “re-evaluate the honorary degrees” given to Schmidheiny and stand-up comedian and actor Bill Cosby. Bill Cosby Also Cited in Letter to Yale Cosby, 80, has spent the last few years defending himself from multiple charges of sexual assault. He went to trial in Pennsylvania this month on charges of aggravated indecent assault, stemming from 2004. Cosby received his honorary degree from Yale in 2003. More than 20 universities around the country already have rescinded a degree given to Cosby. Schmidheiny ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news

Related Links:

AbstractPurposeImmune-checkpoint inhibitors have shown great efficacy in clinical oncology and a very safe toxicity profile. Nevertheless, endocrine toxicity and, in particular, thyroid diseases are among the most frequently reported adverse events. The aim of this study was to assess the utility of a complete endocrine evaluation before starting therapy, in order to predict which patients will develop a thyroid disease and will need a close follow-up.MethodsTwenty-eight patients were treated with ipilimumab and nivolumab for non-small-cell lung cancer or malignant pleural mesothelioma. All patients underwent complete endo...
Source: Endocrine - Category: Endocrinology Source Type: research
The U.S. Food and Drug Administration on Tuesday confirmed the 2017 finding of asbestos contamination in children’s cosmetic products sold by retailers Claire’s and Justice. FDA Commissioner Scott Gottlieb and Susan Mayne, director of the Center for Food Safety and Applied Nutrition, released a joint statement announcing the results of independent tests that confirmed asbestos contamination in three of the product samples from Claire’s and one of the samples from Justice. Asbestos is a naturally occurring mineral often found near talc, a key ingredient in many cosmetic products. Exposure to asbestos can...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Malignant pleural mesothelioma (MPM) is the most common primary pleural tumor and aggressive neoplasm that arises from the mesothelium of the pleura. The prognosis is poor with a median survival of 9.2 to 11.2 months [1 –3], although a better prognosis with a median survival of 5 years is reported for MPM with germline BAP1 mutations [4,5]. In the diagnosis of MPM, it is important to differentiate it from reactive mesothelial hyperplasia (RMH). RMH is a benign process, but sometimes resembles MPM histologically a nd cytologically [6–8].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Thoracic surgeon Dr. Joseph Friedberg at the University of Maryland School of Medicine has identified previously underutilized lymph nodes that could change the way pleural mesothelioma is diagnosed, staged and treated. Friedberg is the head of the Division of Thoracic surgery at Maryland and director of the Mesothelioma and Thoracic Oncology Treatment and Research Center. The findings are based upon the posterior intercostal lymph nodes — a part of the lymphatic system between the ribs near the spine — in 56 mesothelioma patients who were part of a recent clinical trial. Friedberg detailed the groundbreaking f...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
A biotechnology company specializing in innovative cancer therapeutics has opened a clinical trial examining an immunotherapy drug targeting a protein found in 90 percent of malignant mesothelioma tumors. It is the first clinical trial to specifically study a patient population characterized by this protein expression. The target is known as VISTA, a surface protein which inhibits the immune system from working properly and allows the mesothelioma to grow. The drug is CA-170, an orally available molecule and the only anti-VISTA drug being studied today in a cancer clinical trial. And the potential could be huge. “The...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Malignant pleural mesothelioma (MPM) is an aggressive and invariably fatal cancer of the pleural surface that is associated with asbestos exposure [1]. MPM is usually detected at an advanced stage, therefore treatment options are limited to systemic chemotherapy with cisplatin and pemetrexed as the mainstay of palliative treatment for most patients [2]. Prognosis is generally poor for MPM, with a median survival of 12 months in patients treated with pemetrexed and cisplatin chemotherapy [3] but can be very variable, with around 5% of patients surviving more than 5 years [4].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
A coalition of 15 attorneys general are calling for a tougher asbestos reporting rule as part of the recently-revised Toxic Substances Control Act. Maine’s newly elected Attorney General Aaron Frey said last week the coalition wants to eliminate the exemptions for asbestos within the current Chemical Data Reporting guidelines. The attorneys general have asked U.S. Environmental Protection Agency Acting Administrator Andrew Wheeler to initiate a new rulemaking process, helping it comply with their interpretation of the legislation. “This [new] rule would allow the EPA to comply with the Act by giving it the info...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Malignant pleural mesothelioma (MPM) is an aggressive malignancy associated with exposure to asbestos, with poor prognosis and no effective therapies. The strong inhibitory activities of growth hormone-releasing hormone (GHRH) antagonists have been demonstrated in different experimental human cancers, including lung cancer; however, their role in MPM remains unknown. We assessed...
Source: Proceedings of the National Academy of Sciences - Category: Science Authors: Tags: Biological Sciences Source Type: research
Pemetrexed is a pharmacotherapeutic cornerstone in the treatment of non-small cell lung cancer (NSCLC) and mesothelioma. It is mainly excreted renally, but dosing is based on body surface area (BSA) and does not take renal function into account. Impaired renal function (estimated creatinine clearance
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Doctors in China may have uncovered an effective second- or third-line treatment option for patients with malignant pleural mesothelioma. Dr. RongQin Meng, an oncologist at 363 Hospital in Cheng Du, said the investigational drug Apatinib (rivoceranib) could become part of a much-needed advance in mesothelioma treatment. After first- and second-line chemotherapy combinations had failed to slow tumor growth in a 58-year-old woman, Apatinib provided a five-month progression-free survival. “I was surprised at the result,” Meng told The Mesothelioma Center at Asbestos.com. “After taking the drug, the quality o...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
More News: Asbestosis | Cancer | Cancer & Oncology | Colleges | Education | Environmental Health | Fibre | Graduation | Italy Health | Legislation | Lung Cancer | Mesothelioma | Switzerland Health | Universities | Universities & Medical Training | USA Health | Yale